Literature DB >> 13714480

The actions of amylobarbitone sodium, butobarbitone and quinalbarbitone sodium upon insomnia and nocturnal restlessness compared in psychiatric patients.

J M HINTON.   

Abstract

Amylobarbitone sodium, butobarbitone, quinalbarbitone sodium, and a placebo were compared in a controlled, double-blind trial in psychiatric patients with insomnia. An apparatus recording movement in bed is described, with sleep assessments by night nurses and patients. All three barbiturates significantly reduced movement and gave significantly longer, less broken and sounder sleep, without increased incidence of "hang-over." There was no follow-on effect from night to night. With effective doses there was no significant difference between these barbiturates in onset and duration of hypnotic action, although usually accepted as either short or intermediate acting.

Entities:  

Keywords:  BARBITURATES/therapy; INSOMNIA/therapy

Mesh:

Substances:

Year:  1961        PMID: 13714480      PMCID: PMC1482001          DOI: 10.1111/j.1476-5381.1961.tb00300.x

Source DB:  PubMed          Journal:  Br J Pharmacol Chemother        ISSN: 0366-0826


  6 in total

1.  The estimation of motility during rest or sleep.

Authors:  G H COX; E MARLEY
Journal:  J Neurol Neurosurg Psychiatry       Date:  1959-02       Impact factor: 10.154

2.  The effects of meprobamate and pentobarbitone sodium on sleep and motility during sleep: a controlled trial with psychiatric patients.

Authors:  J M HINTON; E MARLEY
Journal:  J Neurol Neurosurg Psychiatry       Date:  1959-05       Impact factor: 10.154

3.  Clinical trial of methyprylone, a piperidine hypnotic.

Authors:  J S STEWART
Journal:  Br Med J       Date:  1956-12-22

4.  The fate of pentobarbital in man and dog and a method for its estimation in biological material.

Authors:  B B BRODIE; J J BURNS; L C MARK; P A LIEF; E BERNSTEIN; E M PAPPER
Journal:  J Pharmacol Exp Ther       Date:  1953-09       Impact factor: 4.030

5.  Physiological performance following a hypnotic dose of a barbiturate.

Authors:  R E GOODNOW; H K BEECHER; M A B BRAZIER; K MOSTELLER; R TAGIURI
Journal:  J Pharmacol Exp Ther       Date:  1951-05       Impact factor: 4.030

6.  A study of hypnotic drugs in patients with chronic diseases; comparative efficacy of placebo; methyprylon (noludar) meprobmate (miltown, equanil) pentobarbial; phenobarbital; secobarbital.

Authors:  L LASAGNA
Journal:  J Chronic Dis       Date:  1956-02
  6 in total
  13 in total

1.  PERSISTENCE OF BARBITURATES.

Authors:  M RUDOLFGDE
Journal:  Br Med J       Date:  1963-11-16

2.  CONTROLLED COMPARISON OF FOUR SEDATIVE DRUGS IN ELDERLY PATIENTS.

Authors:  A N EXTON-SMITH; H M HODKINSON; B W CROMIE; M P CURWEN
Journal:  Br Med J       Date:  1963-10-26

3.  Sleep mechanisms: recent advances.

Authors:  I OSWALD
Journal:  Proc R Soc Med       Date:  1962-11

4.  Patterns of insomnia in depressive states.

Authors:  J M HINTON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1963-04       Impact factor: 10.154

5.  A study of pre-operative sedatives.

Authors:  J Parkhouse; J Mahoney
Journal:  Postgrad Med J       Date:  1968-03       Impact factor: 2.401

6.  The time course of action of single doses of diazepam, chlorpromazine and some barbiturates as measured by auditory flutter fusion and visual flicker fusion thresholds in man.

Authors:  G M Besser; C Duncan
Journal:  Br J Pharmacol Chemother       Date:  1967-06

7.  The time course of barbiturate action in man investigated by measurement of smooth tracking eye movement.

Authors:  H Norris
Journal:  Br J Pharmacol Chemother       Date:  1968-05

Review 8.  Assessment of hypnotics.

Authors:  J M Hinton
Journal:  Proc R Soc Med       Date:  1966

9.  Dependence on hypnotic drugs in general practice.

Authors:  J Johnson; A D Clift
Journal:  Br Med J       Date:  1968-12-07

10.  Ambulatory motor activity monitoring to study the timecourse of hypnotic action.

Authors:  A A Borbély
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.